Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration

Purpose: To evaluate safety and efficacy of the vascular endothelial growth factor binding protein abicipar pegol (abicipar) versus ranibizumab for neovascular age-related macular degeneration. Methods: Phase 2, multicenter, randomized, double-masked comparison (REACH study, stage 3). Patients (n = ...

Descripción completa

Detalles Bibliográficos
Autores principales: Callanan, David, Kunimoto, Derek, Maturi, Raj K., Patel, Sunil S., Staurenghi, Giovanni, Wolf, Sebastian, Cheetham, Janet K., Hohman, Thomas C., Kim, Kimmie, López, Francisco J., Schneider, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306670/
https://www.ncbi.nlm.nih.gov/pubmed/30412448
http://dx.doi.org/10.1089/jop.2018.0062

Ejemplares similares

Ejemplares similares